Watch for ESMO 2026 poster presentation on October 24 and the follow-up webinar on October 29 for detailed immune data and potential partnership commentary. The sustained durability of responses in a small phase 2 trial is encouraging but does not change the need for a larger pivotal trial or a partnership to fund further development.
Price Chart
Executive Summary
Evaxion reported that all patients in the phase 2 trial of personalized cancer vaccine EVX-01 maintained clinical responses at three-year follow-up, with no tumor progression observed during the third year when EVX-01 was given as stand-alone therapy. The data supplements prior two-year results showing a 75% Objective Response Rate and 25% complete response rate, and will be presented at ESMO 2026 on October 24, followed by a webinar on October 29. This is a positive clinical update for a pre-revenue biotech, but the small sample size (16 patients enrolled, 6 of 12 responders in the extension) and lack of financial data or partnership deal limit the near-term stock impact.
Key Facts
- All patients at three-year follow-up in the EVX-01 phase 2 trial maintained clinical responses observed at two-year follow-up, with no tumor progression.
- In the third year, patients received EVX-01 as stand-alone therapy (without KEYTRUDA).
- Two-year data showed a 75% Objective Response Rate with 25% complete response; 92% of patients still responding at two years.
- Data to be presented at ESMO 2026 poster session on October 24, 2026, followed by a webinar on October 29, 2026.
- Trial enrolled 16 patients with advanced melanoma; 6 out of 12 responders continued in the one-year extension.
- EVX-01 is Evaxion's lead clinical asset, a personalized peptide-based cancer vaccine.
Financial Impact
No financial data provided; Evaxion is a clinical-stage pre-revenue company. Positive clinical data may support future partnership discussions but no deal value disclosed.
Risk Factors
- Very small sample size (16 patients enrolled, 6 in extension) limits statistical significance.
- No financial data or partnership deal announced; company remains pre-revenue with need for additional capital.
- Phase 2 data may not predict phase 3 or regulatory outcomes; melanoma treatment landscape is competitive with approved checkpoint inhibitors.
- Forward-looking statements caution about risks including need for capital, clinical trial costs, and inability to enter partnerships.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006678 |
| Document: f6k_101926.htm | 0001171843-26-006678 |
| Document: 0001171843-26-006678-index-headers.html | 0001171843-26-006678 |
| Document: 0001171843-26-006678-index.html | 0001171843-26-006678 |
| Document: 0001171843-26-006678.txt | 0001171843-26-006678 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $3.76 $3.08 | ▼ −18.09% | ▼ −18.80% | $3.04 (−19.15%) |
Oct 19, 2026 8d ago | 6-K | $3.33 $4.05 | ▲ +21.62% | ▲ +21.29% | $3.04 (−8.71%) |
Oct 2, 2026 25d ago | 6-K | $3.20 $3.15 | ▼ −1.56% | ▼ −2.24% | $3.04 (−5.00%) |
Oct 2, 2026 25d ago | Press Release | $3.20 $3.15 | ▼ −1.56% | ▼ −2.24% | $3.04 (−5.00%) |
Sep 14, 2026 6w ago | 6-K | $3.07 $3.04 | ▼ −0.98% | ▼ −0.52% | $3.04 (−0.98%) |
Sep 4, 2026 7w ago | 6-K | $3.12 $3.17 | ▼ −1.60% | ▼ −2.15% | $3.04 (+2.56%) |
Aug 20, 2026 9w ago | 6-K | $3.28 $3.31 | ▲ +0.91% | ▲ +0.51% | $3.04 (−7.32%) |
Aug 20, 2026 9w ago | Press Release | $3.28 $3.31 | ▲ +0.91% | ▲ +0.51% | $3.04 (−7.32%) |
Aug 17, 2026 10w ago | 6-K | $3.13 $3.15 | ▲ +0.64% | ▲ +1.31% | $3.04 (−2.88%) |
Aug 14, 2026 10w ago | 6-K | $3.34 $3.13 | ▼ −6.29% | ▼ −5.81% | $3.04 (−8.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers